Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein assembly factor PIH1D3.

Olcese C, Patel MP, Shoemark A, Kiviluoto S, Legendre M, Williams HJ, Vaughan CK, Hayward J, Goldenberg A, Emes RD, Munye MM, Dyer L, Cahill T, Bevillard J, Gehrig C, Guipponi M, Chantot S, Duquesnoy P, Thomas L, Jeanson L, Copin B, Tamalet A, Thauvin-Robinet C, Papon JF, Garin A, Pin I, Vera G, Aurora P, Fassad MR, Jenkins L, Boustred C, Cullup T, Dixon M, Onoufriadis A, Bush A, Chung EM, Antonarakis SE, Loebinger MR, Wilson R, Armengot M, Escudier E, Hogg C; UK10K Rare Group, Amselem S, Sun Z, Bartoloni L, Blouin JL, Mitchison HM.

Nat Commun. 2017 Feb 8;8:14279. doi: 10.1038/ncomms14279.

2.

Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma.

Sayapina MS, Savelov NA, Karseladze AI, Bulanov AA, Tryakin AA, Nosov DA, Garin AM, Tjulandin SA.

Rare Tumors. 2016 Jun 28;8(2):6241. doi: 10.4081/rt.2016.6241. eCollection 2016 Jun 28.

3.

Pediatric sinogenic epidural and subdural empyema: The role of endoscopic sinus surgery.

Garin A, Thierry B, Leboulanger N, Blauwblomme T, Grevent D, Blanot S, Garabedian N, Couloigner V.

Int J Pediatr Otorhinolaryngol. 2015 Oct;79(10):1752-60. doi: 10.1016/j.ijporl.2015.08.007. Epub 2015 Aug 13.

PMID:
26304070
4.

Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.

Fedyanin M, Tryakin A, Bulanov A, Vybarava A, Tjulandina A, Chekini D, Sekhina O, Figurin K, Garin A, Tjulandin S.

J Cancer Res Clin Oncol. 2015 Jul;141(7):1259-64. doi: 10.1007/s00432-015-1914-5. Epub 2015 Jan 14.

PMID:
25586890
5.

Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors.

Fedyanin M, Tryakin A, Mosyakova Y, Pokataev I, Bulanov A, Zakharova T, Polockii B, Garin A, Tjulandin S.

J Cancer Res Clin Oncol. 2014 Feb;140(2):311-8. doi: 10.1007/s00432-013-1567-1. Epub 2013 Dec 17.

PMID:
24337455
6.

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A.

J Clin Oncol. 2013 Dec 10;31(35):4453-61. doi: 10.1200/JCO.2013.51.0826. Epub 2013 Nov 12.

PMID:
24220555
7.

The Activity of CCL18 is Principally Mediated through Interaction with Glycosaminoglycans.

Krohn S, Garin A, Gabay C, Proudfoot AE.

Front Immunol. 2013 Jul 15;4:193. doi: 10.3389/fimmu.2013.00193. eCollection 2013.

8.

Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN).

David S, Marchais H, Hervé-Aubert K, Bedin D, Garin AS, Hoinard C, Chourpa I.

Int J Pharm. 2013 Oct 1;454(2):660-7. doi: 10.1016/j.ijpharm.2013.05.051. Epub 2013 May 31.

PMID:
23726903
9.

Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.

Fedyanin M, Tryakin A, Bulanov A, Fainshtein I, Zakharova T, Matveev V, Garin A, Tjulandin S.

Urol Oncol. 2014 Jan;32(1):32.e27-33. doi: 10.1016/j.urolonc.2012.12.001. Epub 2013 Apr 28.

PMID:
23628310
10.

Chemokine receptor antagonist development.

Garin A, Johnson Z, Hermant A, Beltran F, Ratinaud Y, Michel A, Krohn S, Gaudet M, Carboni S, Ji H, Missotten M, Leger O, Power C, Proudfoot A.

Methods Mol Biol. 2013;1013:67-92. doi: 10.1007/978-1-62703-426-5_6.

PMID:
23625494
11.

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF.

J Clin Oncol. 2013 Jan 10;31(2):195-202. doi: 10.1200/JCO.2011.38.3331. Epub 2012 Dec 10.

12.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A.

Ann Oncol. 2012 Oct;23(10):2479-516.

PMID:
23012255
13.

[Evolution and revolutionary events in oncology in the end of XX - beginning of XXI century].

Garin AM.

Vestn Ross Akad Med Nauk. 2012;(3):32-6. Review. Russian.

PMID:
22712272
14.

Current status of chemokine receptor inhibitors in development.

Allegretti M, Cesta MC, Garin A, Proudfoot AE.

Immunol Lett. 2012 Jul 30;145(1-2):68-78. doi: 10.1016/j.imlet.2012.04.003. Epub 2012 Apr 20. Review.

PMID:
22698186
15.

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

de Wit R, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L.

J Clin Oncol. 2012 Mar 10;30(8):792-9. doi: 10.1200/JCO.2011.37.0171. Epub 2012 Jan 23.

16.

An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer.

Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ.

Pancreas. 2012 Apr;41(3):374-9. doi: 10.1097/MPA.0b013e31822ade7e.

PMID:
22228104
17.

Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer.

Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M, Zergebel C, Kimball B.

Cancer. 2012 Jul 1;118(13):3244-53. doi: 10.1002/cncr.26419. Epub 2011 Nov 1.

18.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group.

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

19.

Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.

Fedyanin M, Tryakin A, Kanagavel D, Bulanov A, Burova A, Figurin K, Fainshtein I, Sergeev U, Zakharova T, Garin A, Tjulandin S.

Urol Oncol. 2013 May;31(4):499-504. doi: 10.1016/j.urolonc.2011.06.001. Epub 2011 Jul 30.

PMID:
21803619
20.

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.

Urology. 2011 Sep;78(3):620-5. doi: 10.1016/j.urology.2011.05.005. Epub 2011 Jul 20.

PMID:
21764427

Supplemental Content

Loading ...
Support Center